About the Study

For adults with a diagnosis of Major Depressive Disorder (MDD) currently experiencing a Major Depressive Episode (MDE).

The goal of this study is to evaluate the long-term efficacy, safety, and tolerability of BHV-7000, compared to placebo, for the monotherapy treatment of subjects with MDD.
This study is sponsored by Biohaven Pharmaceuticals Inc.

Length of Study:  4 weeks screening period. 6 weeks double-blind treatment period. 2 weeks safety follow-up period.
Total length: About 12 weeks.

Eligibility 

You may be eligible to participate in this study if you:

• are between the ages of 18-75 years old
• meet DSM-5 criteria for Major Depressive Disorder (MDD) diagnosis
• are willing to taper-off and discontinue your current MDD medication.

If chosen for this study, you will be compensated for every study visit that you complete, and we can provide transportation if needed. 

If you are interested in participating in this clinical trial, please call our friendly staff at 773-989-8313 ext. 116 today. You can also fill out the contact form below.